{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:26:13Z","timestamp":1785237973825,"version":"3.55.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>It is well known that G protein\u2013coupled receptors (GPCRs) assume multiple active states. Orthosteric ligands and\/or allosteric modulators can preferentially stabilize specific conformations, giving rise to pathway-biased signaling. One of the most promising strategies to expand the repertoire of signaling-selective GPCR activators consists of dualsteric agents, which are hybrid compounds consisting of orthosteric and allosteric pharmacophoric units. This approach proved to be very promising showing several advantages over monovalent targeting strategies, including an increased affinity or selectivity, a bias in signaling pathway activation, reduced off-target activity and therapeutic resistance. Our study focused on the cannabinoid receptor type 2 (CB<jats:sub>2<\/jats:sub>R), considered a clinically promising target for the control of brain damage in neurodegenerative disorders. Indeed, CB<jats:sub>2<\/jats:sub>R was found highly expressed in microglial cells, astrocytes, and even in some neuron subpopulations. Here, we describe the design, synthesis, and biological evaluation of two new classes of potential dualsteric (bitopic) CB<jats:sub>2<\/jats:sub>R ligands. The new compounds were obtained by connecting, through different linkers, the pharmacophoric portion of the CB<jats:sub>2<\/jats:sub>R positive allosteric modulator (PAM), <jats:bold>EC21a<\/jats:bold>, with that of the CB<jats:sub>2<\/jats:sub>R selective orthosteric agonist <jats:bold>LV62<\/jats:bold>, both developed in our laboratories. A preliminary screening enabled us to identify compound <jats:bold>JR64a<\/jats:bold> as the most promising of the series. Indeed, functional examination highlighted a signaling \u2018bias\u2019 in favor of G protein activation over \u03b2arrestin2 recruitment, combined with high affinity for CB<jats:sub>2<\/jats:sub>R and the ability to efficiently prevent inflammation in human microglial cells (HMC3) exposed to LPS\/TNF\u03b1 stimulation, thus demonstrating great promise for the treatment of neurodegenerative diseases.<\/jats:p>","DOI":"10.3389\/fchem.2022.984069","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T08:24:31Z","timestamp":1664958271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB2R)"],"prefix":"10.3389","volume":"10","author":[{"given":"Rebecca","family":"Ferrisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Polini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawthar A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ortore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Rapposelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saccomanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger G.","family":"Pertwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Laprairie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Chiellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1096\/fj.08-114751","article-title":"Dualsteric GPCR targeting: A novel route to binding and signaling pathway selectivity","volume":"23","author":"Antony","year":"2009","journal-title":"FASEB J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bcp.2018.08.016","article-title":"Cannabinoid pharmacology\/therapeutics in chronic degenerative disorders affecting the central nervous system","volume":"157","author":"Aymerich","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.2174\/138955709787847921","article-title":"Endocannabinoid system: Emerging role from neurodevelopment to neurodegeneration","volume":"9","author":"Basavarajappa","year":"2009","journal-title":"Mini Rev. Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1523\/JNEUROSCI.3923-04.2005","article-title":"A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis","volume":"25","author":"Benito","year":"2005","journal-title":"J. Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"11136","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003","article-title":"Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer\u2019s disease brains","volume":"23","author":"Benito","year":"2003","journal-title":"J. Neurosci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/ACO.0000000000000616","article-title":"An overview of the cannabinoid type 2 receptor system and its therapeutic potential","volume":"31","author":"Bie","year":"2018","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.pbb.2005.01.027","article-title":"The endocannabinoid signalling system: Biochemical aspects","volume":"81","author":"Bisogno","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1111\/febs.15783","article-title":"Allosteric coupling and biased agonism in G protein-coupled receptors","volume":"288","author":"Bock","year":"2021","journal-title":"FEBS J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/1874467207666140714115824","article-title":"Involvement of \u03b2-arrestin-2 and clathrin in agonist-mediated internalization of the human cannabinoid CB2 receptor","volume":"7","author":"Chen","year":"2014","journal-title":"Curr. Mol. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1038\/emm.2015.100","article-title":"CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson\u2019s disease","volume":"48","author":"Chung","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1039\/c8md00448j","article-title":"Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1, 8-naphthyridin-2-(1H)-one-3-carboxamide scaffold","volume":"9","author":"Cooper","year":"2018","journal-title":"Medchemcomm"},{"key":"B12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12974-018-1288-0","article-title":"The human microglial HMC3 cell line: Where do we stand? A systematic literature review","volume":"15","author":"Dello Russo","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.phrs.2009.02.010","article-title":"The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation","volume":"60","author":"Di Marzo","year":"2009","journal-title":"Pharmacol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/s41380-018-0212-4","article-title":"Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation","volume":"25","author":"Donthamsetti","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.bcp.2018.01.002","article-title":"The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D2 receptor","volume":"148","author":"Draper-Joyce","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"105607","DOI":"10.1016\/j.phrs.2021.105607","article-title":"Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB2R modulators in neurodegenerative diseases","volume":"170","author":"Ferrisi","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1021\/acs.jmedchem.8b00368","article-title":"Identification of the first synthetic allosteric modulator of the CB2 receptors and evidence of its efficacy for neuropathic pain relief","volume":"62","author":"Gado","year":"2019","journal-title":"J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9918","DOI":"10.1021\/acs.jmedchem.2c00582","article-title":"Design, synthesis, and biological activity of new CB2 receptor ligands: From orthosteric and allosteric modulators to dualsteric\/bitopic ligands","volume":"65","author":"Gado","year":"2022","journal-title":"J. Med. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"113116","DOI":"10.1016\/j.ejmech.2020.113116","article-title":"Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor","volume":"211","author":"Gado","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1021\/acs.jmedchem.9b01142","article-title":"Application of fluorine and nitrogen-walk approaches: Defining the structural and functional diversity of 2-phenylindole class of cannabinoid 1 receptor positive allosteric modulators","volume":"63","author":"Garai","year":"2020","journal-title":"J. Med. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"19478","DOI":"10.1074\/jbc.R115.662759","article-title":"Novel allosteric modulators of G protein- coupled receptors","volume":"290","author":"Gentry","year":"2015","journal-title":"J. Biol. Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mce.2019.01.019","article-title":"The structural basis of the arrestin binding to GPCRs","volume":"484","author":"Gurevich","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8224","DOI":"10.1021\/jm4005626","article-title":"Therapeutic utility of cannabinoid receptor type 2 (CB2) selective agonists","volume":"56","author":"Han","year":"2013","journal-title":"J. Med. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1083\/jcb.201709069","article-title":"Microglia in Alzheimer\u2019s disease","volume":"217","author":"Hansen","year":"2018","journal-title":"J. Cell. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.jmb.2019.02.004","article-title":"Implications of microglia in amyotrophic lateral sclerosis and frontotemporal dementia","volume":"431","author":"Haukedal","year":"2019","journal-title":"J. Mol. Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/978-981-13-9913-8_13","article-title":"Microglia in Parkinson\u2019s disease","volume":"1175","author":"Ho","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International union of pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3410\/B1-77","article-title":"Bitopic ligands: All-in-one orthosteric and allosteric","volume":"1","author":"Kamal","year":"2009","journal-title":"F1000 Biol. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"23817","DOI":"10.1074\/jbc.M114.582874","article-title":"Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor","volume":"289","author":"Keov","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tips.2012.10.003","article-title":"Bridging the gap: Bitopic ligands of G-protein-coupled receptors","volume":"34","author":"Lane","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cell.2018.12.011","article-title":"Crystal structure of the human cannabinoid receptor CB2","volume":"76","author":"Li","year":"2019","journal-title":"Cell."},{"key":"B32","doi-asserted-by":"publisher","first-page":"8777","DOI":"10.1021\/jm500807e","article-title":"CB2-selective cannabinoid receptor ligands: Synthesis, pharmacological evaluation, and molecular modeling investigation of 1, 8-naphthyridin-2(1H)-one-3-carboxamides","volume":"21","author":"Lucchesi","year":"2014","journal-title":"J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/3-540-26573-2_10","article-title":"Distribution of cannabinoid receptors in the central and peripheral nervous system","volume":"2005","author":"Mackie","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1021\/jm801563d","article-title":"Rational design, synthesis, and pharmacological properties of new 1, 8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists","volume":"52","author":"Manera","year":"2009","journal-title":"J. Med. Chem."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2018-0013","article-title":"Cannabinoids in health and disease: Pharmacological potential in metabolic syndrome and neuroinflammation","volume":"36","author":"Mastinu","year":"2018","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"B36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1021\/acschembio.0c00941","article-title":"Orthosteric and allosteric dual targeting of the nuclear receptor ROR\u03b3t with a bitopic ligand","volume":"16","author":"Meijer","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3390\/ph7121028","article-title":"Role of microglial M1\/M2 polarization in relapse and remission of psychiatric disorders and diseases","volume":"7","author":"Nakagawa","year":"2014","journal-title":"Pharmaceuticals"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1021\/acs.jmedchem.9b01105","article-title":"2016 philip S. Portoghese medicinal chemistry lectureship: Designing bivalent or bitopic molecules for G-protein coupled receptors. The whole is greater than the sum of its parts","volume":"63","author":"Newman","year":"2020","journal-title":"J. Med. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1021\/acs.jmedchem.1c00028","article-title":"Novel approaches, drug candidates, and targets in pain drug discovery","volume":"64","author":"Obeng","year":"2021","journal-title":"J. Med. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3389\/fimmu.2017.01487","article-title":"Targeting cannabinoid signaling in the immune system: \u201cHigh\u201d-ly exciting questions, possibilities, and challenges","volume":"8","author":"Ol\u00e1h","year":"2017","journal-title":"Front. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/life10120333","article-title":"Positive allosteric modulation of CB1 and CB2 cannabinoid receptors enhances the neuroprotective activity of a dual CB1R\/CB2R orthosteric agonist","volume":"333","author":"Polini","year":"2020","journal-title":"Life"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1523\/JNEUROSCI.4628-11.2012","article-title":"Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions","volume":"32","author":"Ramirez","year":"2012","journal-title":"J. Neurosci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.2174\/1568026619666191009164609","article-title":"Recent advances in the drug discovery and development of dualsteric\/bitopic activators of G protein-coupled receptors","volume":"19","author":"Reinecke","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.coph.2016.12.001","article-title":"Functional selectivity and dualsteric\/bitopic GPCR targeting","volume":"32","author":"Schrage","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"108448","DOI":"10.1016\/j.neuropharm.2021.108448","article-title":"Allosteric modulation of the cannabinoid 2 receptor confers seizure resistance in mice","volume":"188","author":"Shapiro","year":"2021","journal-title":"Neuropharmacology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrd.2017.229","article-title":"Biased signalling: From simple switches to allosteric microprocessors","volume":"17","author":"Smith","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B47","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1124\/mol.106.033746","article-title":"A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor","volume":"72","author":"Steinfeld","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"29312","DOI":"10.1074\/jbc.M803801200","article-title":"A novel mechanism of G protein-coupled receptor functional selectivity","volume":"283","author":"Valant","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1073\/pnas.1320962111","article-title":"Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist","volume":"111","author":"Valant","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1523\/JNEUROSCI.23-04-01398.2003","article-title":"Nonpsychotropic cannabinoid receptors regulate microglial cell migration","volume":"23","author":"Walter","year":"2003","journal-title":"J. Neurosci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrd4052","article-title":"Emerging paradigms in GPCR allostery: Implications for drug discovery","volume":"12","author":"Wootten","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1111\/ejn.13414","article-title":"Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic post-ischemic pain model of complex regional pain syndrome type I in rats","volume":"44","author":"Xu","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"20405","DOI":"10.1038\/s41598-020-77175-y","article-title":"In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa","volume":"10","author":"Zagzoog","year":"2020","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2022.984069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T08:24:33Z","timestamp":1664958273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2022.984069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":53,"alternative-id":["10.3389\/fchem.2022.984069"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2022.984069","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"984069"}}